Maha Hussain, MD, FACP

Articles

Dr. Hussain on the Need for Effective Treatment in Nonmetastatic CRPC

October 20th 2020

Maha Hussain, MD, FACP, FASCO, discusses the need for treatment that elicits an overall survival benefit in patients with nonmetastatic castration-resistant prostate cancer.

Dr. Hussain on the Need for Collaboration to Cure Prostate Cancer

October 6th 2020

Maha Hussain, MD, FACP, FASCO, discusses the need for collaboration to cure patients with prostate cancer.

Dr. Hussain on the Rationale to Target the DNA Repair Pathway in mCRPC

September 29th 2020

Maha Hussain, MD, FACP, FASCO, discusses the rationale for targeting the DNA repair pathway in metastatic castration-resistant prostate cancer.

Dr. Hussain on the Importance of Genomic Profiling in mCRPC

September 25th 2020

Maha Hussain, MD, FACP, FASCO, discusses the importance of genomic profiling in metastatic castration-resistant prostate cancer.

Dr. Hussain on the Clinical Impact of the PROfound Trial in mCRPC

September 24th 2020

Maha Hussain, MD, FACP, FASCO, discusses the clinical impact of the phase 3 PROfound trial in metastatic castration-resistant prostate cancer.

Dr. Hussain on the Safety Profile of Olaparib in the PROfound Trial in mCRPC

September 22nd 2020

Maha Hussain, MD, FACP, FASCO, discusses the safety profile of olaparib as observed in the phase 3 PROfound trial in men with metastatic castration-resistant prostate cancer.

Dr. Hussain on Interest in Using PARP Inhibitors in Prostate Cancer

September 6th 2018

Maha Hussain, MD, FACP, FASCO, Genevieve Teuton Professor of Medicine, Deputy Director, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, discusses the interest in using PARP inhibitors in patients with prostate cancer.

Dr. Hussain on the Treatment of Nonmetastatic CRPC

July 25th 2018

Maha Hussain, MD, FACP, FASCO, Genevieve Teuton Professor of Medicine, Deputy Director, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, discusses the treatment of patients with nonmetastatic castration-resistant prostate cancer.

Dr. Hussain Discusses Findings With PARP Inhibitors in Prostate Cancer

June 5th 2018

Maha Hussain, MD, FACP, FASCO, Genevieve Teuton Professor of Medicine, Deputy Director, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, discusses findings with PARP inhibitors in prostate cancer.

Dr. Hussain on the Importance of Next-Generation Sequencing in Prostate Cancer

March 24th 2018

Maha Hussain, MD, FACP, FASCO, Genevieve Teuton Progessor of Medicine, Deputy Director, Robert H. Lurie Comprehensive Cncer Center, Northwestern University Feinberg School of Medicine, discusses the importance of next-generation sequencing in prostate cancer.